Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs BioNTech SE - ADR (BNTX) Price & Performance

Build A Bear Workshop IncTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs BioNTech SE - ADR — how do they compare? Build A Bear Workshop Inc trades at $33.54 (market cap $412.61M), while BioNTech SE - ADR trades at $90.28 (market cap $22.86B). The key difference: BioNTech SE - ADR is far larger — about 55.4× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.8% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BBWBNTX
Market Cap
$412.61M$22.86B
Sector
Consumer CyclicalHealth
52-Week High
$75.85$119.34
52-Week Low
$29.84$83.89
Enterprise Value
$512.05M$6.53B
Dividend Yield
2.8%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $33.62, down 2.32% with a bullish technical signal and strong valuation metrics including a P/E of 7.71 and P/S of 0.81. The company maintains solid profitability with 10.48% net margins and 35.87% ROE, while recent earnings have consistently beaten expectations. CEO transition to Chris Hurt in June 2026 and new product launches support growth initiatives.

BBW presents compelling value with analyst consensus target of $62.50 (86% upside) and 73% buy ratings. Strong fundamentals and debt-free balance sheet support long-term growth, though near-term headwinds include consumer spending pressure and international expansion execution risks.

BioNTech SE - ADR

BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.

The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX